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Edited by Barry HalliwellAbstract The production of nitric oxide (NO) in liver disease
and its role in vascular control has been a subject of much inter-
est in recent years. However, the activity of guanylate cyclase
(GC), the enzyme activated by NO has received little attention
with regard to liver disease. In this study we have utilised a quan-
titative cytochemical technique to examine the activity of GC on
a per cell basis in a rat model of cirrhosis. Our results show a
signiﬁcant reduction in GC activity, indicating that vascular reg-
ulation is likely to be substantially aﬀected irrespective of NO
generation in this disease model.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The role of nitric oxide (NO) as a vascular mediator is well
described; NO stimulates guanylate cyclase (GC) activity in
smooth muscle cells to produce cyclic guanosine monophos-
phate (cGMP), facilitating vascular relaxation [1,2]. Evidence
suggests that NO production is decreased in the cirrhotic liver
and that this contributes to a reduction in blood ﬂow [3]. How-
ever, there is scant information addressing the role of GC as a
modulator of local blood ﬂow in cirrhosis and indeed its regu-
latory role in normal liver function. Herein, we use the estab-
lished bile duct ligation (BDL) model [4] to examine whether
there is modulation of hepatic GC activity in cirrhosis. We sug-
gest that, in addition to NO production, the regulation of GC
activity is pivotal to the control of blood ﬂow within the liver,
and that factors restricting GC activity would to be detrimen-
tal to hepatic function.
To investigate the NO-stimulated activity of GC at the cellu-
lar level we have utilised a quantitative cytochemical (QC)
technique [5–8]. This is an extremely sensitive method, which
allows examination of GC activity in individual cells within tis-
sues with complex architecture. In this method, tissues are
cryo-preserved, sectioned and then immediately reacted on
the microscope slide. The chosen enzyme reaction is optimised*Corresponding author. Fax: +44 0 2073800405.
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doi:10.1016/j.febslet.2006.02.080to produce a precipitated chromophore; the resultant optical
density is stoichiometrically related to the speciﬁc cellular
enzymatic activity. This methodology allows regional exami-
nation of tissues and the quantiﬁcation of activity in individual
cell types [9,10].
The aim of this study was to utilise a QC method to evaluate
GC activity to determine the ability of the liver to respond to
hepatic production of NO. The speciﬁcity and sensitivity of
this technique provides the opportunity to investigate whether,
and to what extent, cGMP production may be altered in cir-
rhosis.2. Materials and methods
2.1. Animal studies
All studies were conducted according to Home Oﬃce guidelines un-
der the Animals in Scientiﬁc Procedures Act 1986. Male Sprague–
Dawley rats (230–280 g, Charles Rivers Ltd.) were given free access
to normal rodent chow and water, with a light dark cycle of 12 h,
19–23 C, and humidity of approximately 50%.
BDL was achieved by making a midline abdominal incision under
anaesthesia [4]. In the BDL group, the common bile duct was isolated,
triply ligated with 3–0 silk, and sectioned between the ligatures. The
sham-operated (control) group were anesthetised, operated upon, but
did not have their bile duct ligated. After BDL, all animals continued
to gain weight and were comparable with sham-operated controls. The
overall mortality in both groups was less than 10% and occurred within
36 h of the operation.
The animals were killed by exsanguinations under anaesthesia, with
blood and liver tissue collected for analysis. All studies were performed
on liver tissue at 25–28 days post BDL or sham procedure, and 6 ani-
mals were used in the ﬁnal analysis in each group.
2.2. Tissue NOS activity determination
Tissue for this assay was ﬂash-frozen in liquid nitrogen and stored at
80 C until use. The method used was a variation on the widely re-
ported 3H-arginine to 3H-citrulline assay [1,2], modiﬁed for liver tissue.
Brieﬂy, liver tissue was homogenised in ice-cold HEPES buﬀer
(20 mM, pH 7.4) containing EDTA (1 mM); sucrose (250 mM); valine
(60 mM); protease inhibitor cocktail (1 ml/20 g tissue); and PMSF
(3.4 mg/ml). This was then centrifuged (1000 · g, 10 min, 4 C) and
the supernatant retained and measured for protein content using the
Biuret method [11]. For NOS activity, 5 ll of the supernatant was incu-
bated with a reaction medium (40 ll) containing: Tris–HCl buﬀer
(30 mM, pH 7.4); NADPH (1.25 mM); 3H-arginine (10 lCi/ml, Amer-
sham, UK); norvaline (5 mM); and either CaCl2 (400 lM) or EGTA
(600 lM). The mixture was incubated at 30 C for 30 min before stop-
ping with ice-cold citrate buﬀer (1 ml, 50 mM, pH 5) containing EDTA
(1 mM). The arginine:citrulline ratio was determined after thin layer
chromatography separation on silica plates (Kieselgel 60, Merck,
Darmstadt, Germany). Non-tritiated amino acids were added to aidblished by Elsevier B.V. All rights reserved.
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mixture of CHCl3:MeOH:NH4OH:H2O (ratio of 10:45:20:10), after
drying the plates were developed using ninhydrin (0.5% in butanol).
The individual spots were collected and the scintillation activity mea-
sured (Ultima Gold scintillant, Perkin–Elmer, Boston, MA. Using a
Tri-Carb 2100TR, liquid scintillation analyser, Packard Biosciences,
Berks, UK). Activity is expressed as lmol citrulline/mg protein/h.2.3. Cytochemical assessment of GC activity
For QC analysis, small fresh liver segments (0.5 cm3) were coated in
a 5% aqueous solution of polyvinyl alcohol (PVA, Grade G04/140,
Wacker chemicals Ltd., UK) and chilled to 70 C by immersion in
n-hexane (HPLC grade. Rathburn, Peebleshire, Scotland) in an outer
bath of solid carbon dioxide in ethanol. The samples were then stored
at 80 C for less than 28 days before analysis [5–7].
14 lm tissue sections were cut in a cryostat (Bright’s Instruments
Huntingdon, UK), using a microtome ﬁtted with an automatic drive
to ensure constant section thickness. The cabinet temperature was
maintained at 25 C, and the cutting blade further cooled by packing
the haft in solid CO2. Sections were ﬂash dried onto uncoated glass
slides before reaction for enzyme activity.
GC activity was disclosed according to the method of Mehdizadeh
et al. [6]. Brieﬂy, fresh unﬁxed cryostat sections were reacted in med-
ium containing: guanosine triphosphate (GTP, 10 mM); sodium azide
(2.5 mM); sodium acetate (0.2 mM); manganese chloride (20 mM); so-
dium ﬂuoride (10 mM); L-p-bromotetramisole (0.4 mM); in Tris buﬀer
(pH 7.0, 0.2 M) containing 35% polypep 5115. Tissue sections were re-
acted for 30 min at 37 C before stopping by immersion in ice-cold
polypep 5115 (2%). Under these conditions, GC enzyme activity results
in the generation of pyrophosphate which was trapped by the addition
of freshly prepared lead ammonium citrate/acetate solution at a ﬁnal
concentration of 32 mg/ml [7]. The resultant lead phosphate precipitate
was subsequently disclosed by immersion in ammonium polysulﬁde
(0.5%) for 1 min, to produce a coloured (brown) reaction product, be-
fore repeated washing in distilled water then allowed to air dry. Sec-
tions were mounted in absolute glycerine for measurement.
To measure the maximum extent to which endogenous hepatic NOS
activity contributes to the level of GC activity disclosed, serial sections
were incubated in ‘full’ reaction medium (described above) that was
further supplemented with NO synthase substrates, namely: 1 mM
NADPH, 5 mM arginine, and 3 mM norvaline (to inhibit endogenous
arginase activity). The increased pyrophosphate production above that
evident in serial sections reacted for GC activity alone, is therefore a
measure of the level of GC activity attributable to endogenous NOS
activity.
Control studies included reacting sections incubated in medium sup-
plemented with the NOS inhibitor L-NAME [12] to demonstrate that
the action of arginine and NADPH occurred via NOS stimulation.
Complimentary use of the NO donor, 50 lM DEANO
((CH3CH2)2N(NONO)Na) [13], in place of NOS substrates, was used
to evaluate the action of direct, non-enzymatic NO donation upon
overall GC activity in additional serial sections.
A known inhibitor of GC activity, ODQ [14], was also added to the
reaction medium (1 mM), in both the presence and absence of GC acti-
vators. This was included to demonstrate the speciﬁcity of the reaction
for GC activity and as a means of determining whether background
levels of GC-independent phosphate generation were modulated by
BDL treatment.
Unless otherwise stated, all chemicals and reagents were obtained
from the Sigma Chemical Company (Poole, UK).
GC activity was measured in individual histologically deﬁned hepa-
tocytes using a Vickers M85A scanning and integrating microdensi-
tometer (Biorad Instruments, York, UK), ﬁtted with a 40· 0.6 NA
objective, using spot size 1, a 20 lm mask and k = 585 nm [5,6]. Activ-
ity was expressed as units of mean integrated extinction/cell multiplied
by 100 (MIE · 100). Measurements of GC activity were made in 15
individual cells in each of duplicate sections of tissue segments col-
lected from the left medial lobe of the liver.Fig. 1. NOS activity in liver tissue homogenates from BDL and
control animals as determined by the conversion of 3H-arginine to 3H-
citrulline. Data are expressed as mean (±S.E.M.) scintillation counts/h/
mg of protein, determined over a 30-min period (n = 6 per group). No
signiﬁcant diﬀerence was found between these two groups.2.4. Statistical analysis
Data are shown as mean ± standard error of the mean (S.E.M.).
Two-tailed unpaired t tests were used to deﬁne diﬀerences between
means of normally distributed data of equal variance, using a commer-
cially available package (GraphPad Prism, version 4.0; GraphPadSoftware, Inc., SanDiego, CA, USA). For statistical evaluation of data
that was not normally distributed, a Mann–Whitney test was used.
Dose concentration response curves were calculated using non-linear
regression. Results were considered signiﬁcant if P < 0.05.3. Results
3.1. Animal studies
Animals in both groups continued to gain weight at similar
rates following surgery. After 28 days the BDL-treated animals
(305–345 g) were only slightly heavier than the control group
(270–355 g) and this diﬀerence, although not statistically sig-
niﬁcant, was attributed to the presence of ascites.
3.2. Tissue NOS activity determination
The induction of liver cirrhosis was conﬁrmed through the
appearance of steatosis [15] and large increases in connective
tissue that were apparent in the BDL group. An analysis of tis-
sue NOS activity using 3H-arginine, demonstrated that the
induction of cirrhosis following BDL fails to produce any sig-
niﬁcant changes in the level of NOS activity in the soluble frac-
tion extracted from the tissue homogenates (Fig. 1). Though,
after centrifugation of the tissue homogenates, the protein con-
centration of the supernatants was found to be comparable in
the two groups (data not shown). 3H-Ornithine production
was also observed in both control and BDL treated groups,
indicating that despite the presence of norvaline some arginase
activity remained. 3H-Arginine was still present at the end of
the study period in all samples examined, demonstrating that
NOS activity was not limited by a lack of substrate availability
in this assay.
3.3. Cytochemical assessment of GC activity
Measuring GC activity by QC provides an alternative strat-
egy to disclose changes in the NOS-GC system and provides an
activity measurement on a per cell basis. This may be particu-
larly pertinent when measuring diﬀerences between normal
and diseased tissues in which pathological changes are associ-
ated with marked changes in histology and tissue architecture,
such as those addressed herein. It is apparent that the ﬁbrotic
areas, evident in the H&E stained sections, showed little or no
GC activity (Fig. 2), and that although the general level of
activity appears lower in the livers of the BDL group, individ-
Fig. 2. Panels A and B show haematoxylin and eosin stained sections (16·) of liver tissue taken from a control and BDL animal, respectively. In
section B areas of ﬁbrosis can be clearly seen. Panels C (control) and D (BDL) show corresponding liver sections following a quantitative
cytochemistry study for GC activity, in which the brown colouration indicates the presence of phosphate.
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activity.
Microdensitometric assessment of GC activity in both the
sham and BDL groups disclosed a signiﬁcant increase in mea-
surable GC activity/cell following the addition of NOS sub-
strates (P < 0.001 in each case, Fig. 3). This indicates that
endogenous NOS is capable of promoting increases in GC
activity in liver cells in both control and BDL rats. These mea-
surements also show that BDL treatment signiﬁcantly reduces
both basal and NOS-activated GC activity to levels signiﬁ-
cantly below those in sham-operated control animalsFig. 3. Quantitative cytochemistry measurement for GC activity
assessed by determination of pyrophosphate production in tissue slices
from control and BDL treated animals, in the presence and absence of
substrates for NOS (arginine and NADPH). Data are expressed as
mean ± S.E.M., n = 6 in each case. *** signiﬁes P < 0.001.(P < 0.001). It is of note that the relative level of enhancement
in GC activity, induced by the supplementation of substrates
for endogenous NOS, was similar in both the BDL and sham
control groups (sham = 29.9%, BDL = 26.5%). This suggests
that BDL results in a reduction of GC activity per cell, but that
this is achieved without aﬀecting the capacity for the GC pres-
ent to be activated by endogenous NOS.
In order to further address these issues, we used the NO do-
nor, DEANO, to stimulate GC activity in a manner that was
independent of endogenous NOS activity. Firstly we examined
the eﬀect of diﬀering concentrations of DEANO on GC activ-
ity in sections of liver from control rats. This showed that
DEANO induced increases in GC activity in control tissues
in a log dose-dependent manner (Fig. 4). Following such cali-
bration, we supplemented the GC reaction media with a con-
centration of DEANO that would produce an excess of NO.Fig. 4. Quantitative cytochemistry measurement for GC activity,
assessed by determination of pyrophosphate production in tissue slices
from control animals in the presence of increasing concentrations of
DEANO. Data are expressed as individual data points taken from
sections taken in triplicate from three animals. The line indicates a log
non-linear regression curve ﬁt where r2 = 0.97.
2126 N.A. Davies et al. / FEBS Letters 580 (2006) 2123–2128Such supplementation was found to stimulate similar increases
in GC activity/cell as those induced by NOS substrate supple-
mentation (Fig. 5A and B).
The eﬀect of increasing concentrations of DEANO on GC
activity in serial sections of a control liver demonstrates that
the greater NO availability, engendered by inclusion of
increasing concentrations of DEANO, produced increased
density of reaction product (activity) which is particularly
apparent in cells at the edges of the sinusoids (Fig. 6). This sug-
gests that endogenous NO generation in control tissue is capa-
ble of inducing maximal increases in GC activity levels.
Furthermore, this NOS-stimulated increase in GC activity
was prevented in the presence of the NOS inhibitor L-NAMEFig. 5. Quantitative cytochemistry measurement for GC activity
assessed by determination of pyrophosphate production in tissue slices
from (A) Control and (B) BDL treated animals, in the presence and
absence of substrates for NOS (arginine and NADPH), DEANO and
NOS substrates plus the NOS inhibitor L-NAME. Data are expressed
as mean ± S.E.M., n = 6 in each case. ** signiﬁes P < 0.01.
Fig. 6. Illustrative example of the staining density obtained with
increasing concentrations of DEANO in 14 lm sections of liver
obtained from a control animal (at 10· magniﬁcation).(Fig. 5). Indeed, the addition of L-NAME decreased baseline
GC activity below that found in the absence of NOS substrates
(P < 0.01 in both sham and BDL groups), suggesting that a
proportion of this basal GC activity is attributable to the pres-
ence of endogenous NOS activity.
To conﬁrm that the observed reaction product was depen-
dent upon the activity of GC, the eﬀect of ODQ, an inhibitor
of GC, was examined. This showed that the level of GC activityFig. 7. Quantitative cytochemistry measurement for GC activity
assessed by determination of pyrophosphate production in tissue slices
from control animals in the presence and absence of NOS substrates,
expired (ex) DEANO, and the speciﬁc GC inhibitor ODQ. Data are
expressed as mean ± S.E.M., n = 3 in each case, *** indicates P < 0.001
where indicated.
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(Fig. 7). The remaining background activity is likely to be
due to the spontaneous GTP breakdown (data not shown).
GC activity, assessed in the presence of either NOS substrates
or DEANO, was also similarly inhibited by the inclusion of
ODQ (Fig. 7). This demonstrates that GC activity is required
for both the NOS-dependent and NO donor-dependent in-
crease in measured optical density. It was also found that a
solution of DEANO in which the NO donating capacity had
expired with prolonged storage, had no eﬀect on GC activity.4. Discussion
The results of his study have consistently shown that hepa-
tocellular GC activity in the BDL treated animals was signiﬁ-
cantly lower than in controls. Stimulation of GC by NO
increased activity to a similar extent in both control and
BDL groups. Yet in all cases the total GC activity in the
BDL animals remained lower. Coupled with the formation
of large ﬁbrotic areas in which GC active cells were almost
negligible, this indicates that overall hepatic GC activity is se-
verely restricted following BDL.
NOS activity in cirrhosis has been the subject of much inves-
tigation, and it has been suggested that decreased hepatic NO
generation may be responsible for reduced vascular control
and increased intra-hepatic resistance [16]. In this study we
found no diﬀerence in NOS activity between the two groups.
This similarity in NOS activity between the control and BDL
treated groups was found when assessed with an isolated max-
imal rate assay. A similar ﬁnding was made by Wei et al. [17],
although in this study it was found that though there was no
change in total NO production, the activity of constitutive
NOS was reduced and iNOS increased in BDL animals com-
pared to controls. It is also interesting to note that in a related
study by the same authors; the chronic administration of an
iNOS speciﬁc inhibitor (though not a non-speciﬁc NOS inhib-
itor) ameliorated liver injury in a BDL rat [18]. However, it is
important to consider that in both this study and that by Wei
et al. [17], only the soluble fraction of the tissue homogenate
was analysed after removal of the connective tissue, and that
the amount of NOS per gram of liver tissue may in fact be re-
duced in vivo. Furthermore, it is important to stress that this
assay precludes the eﬀect of endogenous competitive NOS
inhibitors such as ADMA [19] which may have been present
prior to tissue processing.
A limitation of homogenate assays is that they cannot exam-
ine the speciﬁc activity in the diﬀerent cell types present within
a tissue. QC is not restricted in this manner [20]. Furthermore,
though it is possible to add inhibitors/activators to homoge-
nate assays, again these may have diverse cell speciﬁc eﬀects
that remain undetectable. Our investigations in the cirrhotic li-
ver, demonstrate the clear advantage in examining activity per
cell rather the common standardisation methods for homoge-
nate assays. These often utilise tissue weight or protein con-
tent, both of which would skew the results due to the
presence of ﬁbrotic lesions.
It is clear from our ﬁndings that irrespective of the level of
NO generation in the liver, its eﬃcacy would be reduced by
a decreased level of GC activity. This suggests that in situations
where the NO availability is reduced, the eﬀect on vascular reg-
ulation would be magniﬁed via an inability to produce cGMP.Felipo and co-workers have previously shown that GC
activity is reduced by up to 50% in the brain of BDL rats fol-
lowing NO stimulation [21]. Similarly, brain GC activity was
also reduced in a portcaval anastamosis rat model of acute li-
ver failure, but the magnitude of this eﬀect varied across diﬀer-
ent regions [22,23]. Other studies by this group have linked the
eﬀects on GC to hyperammonemia [23,24]. We found that the
plasma ammonia was slightly, but not signiﬁcantly, elevated in
the BDL group compared to controls (23%, data not shown).
We are therefore unable to make any deﬁnitive conclusions
regarding ammonia aﬀecting hepatic GC activity.
Previous studies have examined the activity of GC in
homogenates in various tissues in BDL models [25,26]. This
is the ﬁrst study however, to directly examine GC activity in
the liver of BDL rats. It is also the ﬁrst QC study to measure
GC activity in individual hepatocytes, and demonstrates
marked decreases associated with the development of cirrhosis.
This is an important point considering the large tracts of ﬁbro-
tic tissue containing few GC active cells. Our study suggests
that it is likely that in this situation regulation of blood ﬂow
would be severely compromised, and that any eﬀects of NOS
substrates or NO donors acting via their inﬂuence on NOS
activity would be limited [27]. These considerations are also
relevant to NO produced independently from NOS, such as
that generated by the reaction between nitrite (NO2) and
deoxyhaemoglobin [28]. Gladwin and co-workers have sug-
gested that this mechanism may facilitate NO-stimulated vaso-
relaxation in areas of low oxygen tension [29–31]. This
mechanism however, presumably relies on the down-stream
stimulation of GC to aﬀect a response, and is therefore likely
to remain limited in the cirrhotic liver.
The use of a phosphodiesterase (PDE) inhibitor was found to
improve memory in a hyperammonaemic rat model in which
GC activity was diminished [32]. It may be that the addition
of PDE inhibitors to prolong the eﬀective lifetime of cGMP
may prove beneﬁcial, particularly in the presence of an NO
donor. This combination may prove to be a useful therapeutic
option for the future, particularly if the eﬀects could be targeted
to the liver. However, unfortunately it would not be possible to
examine the eﬀects of PDE inhibitors with this technique as it is
the alternate reaction product (phosphate) which is measured.
In conclusion, we have demonstrated using quantitative
cytochemistry, that GC activity is signiﬁcantly diminished in
hepatocytes of a cirrhotic liver, and that this is regardless of
the amount of NO generated. The implication of this study
is that the control of vasodilation in the cirrhotic liver is ulti-
mately dependent on the amount and activity of GC, and
not exclusively due to the availability of NO.References
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